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a  b  s  t  r  a  c  t
Background:  Although  aminolevulinic  acid (ALA)-induced  protoporphyrin  IX  (PpIX) photodynamic  ther-
apy (PDT)  is  an  effective  FDA-approved  therapy  for  actinic  keratosis  (AK),  a substantial  fraction  of  patients
(up  to 25%)  do not  respond  to treatment.  This  study  examined  the  feasibility  of using pre-treatment
measurements  of  PpIX  concentration  in  AK lesions  to  predict  response  of  ALA-PpIX  PDT.
Methods:  A  non-invasive  ﬁber-optic  ﬂuorescence  spectroscopy  system  was  used  to  measure  PpIX  con-
centration  in  patients  undergoing  standard-of-care  ALA-PDT  for AK.  All  patients  provided  assessments  of
pain  at  the  time  of  treatment  (n = 70), and  a subset  reported  pain  and  erythema  48–76 h  after  treatment
(n  =  13).
Results:  PpIX  concentration  was signiﬁcantly  higher  in  lesions  of  patients  reporting  high  levels  of  pain
(VAS  score  ≥5)  immediately  after  treatment  vs.  patients  reporting  pain  scores  below  VAS  = 5 (p  <  0.022)
(n =  70).  However,  pain  was  not  an  exclusive  indicator  of  PpIX  concentration  as  many  patients  with  low
PpIX  concentration  reported  high  pain. In a subpopulation  of patients  surveyed  in  the  days  after  treat-
ment  (n  =  13),  PpIX  concentration  measured  on the  day  of  treatment  was uncorrelated  with  pain-reported
immediately  after  treatment  (r = 0.17,  p < 0.57),  but  positive  correlations  were  found  between  PpIX con-
centration  and  patient-reported  pain  (r  = 0.55,  p < 0.051)  and  erythema  (r  =  0.58,  p  < 0.039)  in the  48–72 h
following  treatment.
Conclusions:  These  data  suggest  that  in  vivo  optical  measurements  of  PpIX  concentration  acquired  before
light delivery  may  be an  objective  predictor  of  response  to  ALA-PpIX  PDT. Identiﬁcation  of non-responding
patients  on the  day  of  treatment  could  facilitate  the  use  of interventions  that may  improve  outcomes.
© 2015  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. Introduction
Actinic keratoses (AK) are pre-malignant lesions that tend to
ppear in sun-exposed areas of skin. Medical intervention may  be
rescribed either for cosmetic purposes or to prevent progression
o squamous cell carcinoma [1]. Treatment options include curet-
age and cryosurgery [2], which are both effective at lesion removal
ut result in scarring which makes these options unattractive for
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widely-distributed lesions on sensitive regions such as the face
and scalp. Topical chemical therapies (e.g. 5-ﬂuorouracil) are also
effective, but are associated with undesirable side effects including
dryness, erythema, pain, or edema [2,3]. Alternatively, photody-
namic therapy (PDT) is a light-based treatment modality [4] which
does not induce scarring or cumulative toxicity, allowing repeated
treatments to the same areas [5–8]. In general, ALA-PpIX PDT is
effective vs. alternative treatment options [9], but results in incom-
plete responses in a substantial number of patients (i.e. 11–25%)
[10–12]. The origins of this variation and methods to have an early
prediction of response are examined in this study.
ALA-induced PpIX PDT is approved by the U.S. Food and
Drug Administration (FDA) for treatment of nonhyperkeratotic AK
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esions on the face and scalp. The FDA-approved treatment protocol
peciﬁes an 11–16 h. incubation time between the topical appli-
ation of ALA and the administration of treatment light. Recent
tudies have reported that similar efﬁcacy may  be obtained with
n incubation time of 1–3 h [13–17] and are now used as part of
tandard clinical practice, but the effect of the short-incubation
ime on PpIX accumulation has not been well characterized in a
arge patient population. Some studies used measurements of ﬂu-
rescence intensity to evaluate PpIX generation in AK lesions over
hese short ALA-contact times and have reported substantial inter-
atient variability [18–20]. Interestingly, PpIX accumulation was
igher in patients reporting high pain on the day of treatment [19],
nd threshold amounts have been shown to be predictive of ery-
hema [18,20] and lesion clearance [19]. However, these previous
tudies were limited to relatively small patient populations (i.e. <20
atients). Furthermore, most PpIX dosimetry studies used instru-
ents that did not correct for the effects of background optical
roperties, which can have a major impact on the quantiﬁcation of
pIX concentration. Recently, we reported on a novel instrument
hat corrects for the confounding effects of background optical
roperties and tissue autoﬂuorescence to provide a metric of PpIX
ield that is directly comparable between patients [20]. In the cur-
ent study, we deploy this instrument to examine the predictive
otential of pre-treatment dosimetry in a 70-patient clinical study.
The primary objective of the present study was  to determine
f quantitative PpIX ﬂuorescence in lesions of patients undergo-
ng short-contact time ALA-induced PpIX PDT treatment may  be
 reliable biomarker of treatment response. The data were used
o analyze inter-patient variability in PpIX available in targeted
esions at the time of treatment, as well as differences between
reatment locations (e.g. lesions on face, vs. lesions on the hands,
rms, and legs), and also to consider PpIX production in contralat-
ral locations with no identiﬁed pathology. This study utilized pain
eported by the patient as the metric of treatment response, with all
atients reporting pain experienced at the time of treatment, and
 subset of patients enrolled in a follow-up survey to report pain
nd erythema 2–3 days following treatment. Correlations between
eported metrics of pain and PpIX concentration at the time of
reatment are reported.
. MethodsThe study protocol was approved by the Institutional Review
oard (IRB) of Dartmouth Hitchcock Medical Center (DHMC).
ighty-two patients with AK identiﬁed during standard clinical
xamination in a local dermatology practice (MS  Chapman, DHMC)
Fig. 1. PpIX yield optically quantitated in AK and non-AK sites for all patients (n =ynamic Therapy 12 (2015) 561–566
were enrolled. Informed consent was obtained in writing from
patients prior to initiation of standard-of-care treatment. Some
patients did not complete the study due to instrumentation error
not able to record data (n = 2), recording poor quality optical signals
(n = 7), or due to optical measurement of a non-AK lesion within the
ﬁeld (n = 5). In this study ‘patient number’ refer to the patients that
completed the study.
The PDT procedure began with topical application of ALA (Levu-
lan Kerastick, DUSA Pharmaceuticals, Wilmington, MA)  to the area
of skin containing visible lesions. One lesion within the ﬁeld to
be treated was selected by the clinical staff (MS Chapman and/or
KL Sheehan, DHMC) to be optically measured to estimate PpIX
concentrations during the course of treatment. After ALA appli-
cation, patients were instructed to wait for 1 h in the outpatient
waiting room, to avoid exposure to direct sunlight. Patients were
then treated with the FDA-approved therapeutic blue light source
(BLU-U Blue Light Photodynamnic Therapy Illuminator, DUSA Phar-
maceuticals) with a standardized ﬂuence rate of 10 mW/cm2 for
8–16 min  for each patient. Immediately following treatment, all
patients were asked to assess their maximal pain level experienced
during treatment using the visual analog scale (VAS) from 0 to 10,
with 0 being no pain and 10 being the worst pain. A subset of
patients (n = 13) were contacted via phone to assess the pain expe-
rienced in the days following treatment; those patients provided
both VAS assessment of pain and a qualitative assessment of ery-
thema (0—none, 1—mild, 2—severe) between the administration of
therapy and the follow up.
Details of the optical measurement device have been described
in detail previously [20], and are outlined here in brief. The sys-
tem included a tungsten halogen white light source (Ocean Optics,
Dunedin, FL) and a 635 nm laser diode (WorldStarTech, Toronto,
Ontario, CA). These sources were coupled into a ﬁber optic probe
with 260-m between source-and detector ﬁbers that were 200-
m ﬁbers in diameter (R200-7-UV/VIS, Ocean Optics, Dunedin, FL).
The sources were coupled via a ﬁber switch to the source ﬁber,
and collected light was  passed ﬁrst through a ﬁlter wheel (Thor-
Labs FW102C, Newtown, NJ) allowing source-selected attenuation
of excitation source light in the collected remission into a spec-
trophotometer (USB4000, Ocean Optics). Optical measurements
were performed on the selected lesion and on a second location
that did not present any identiﬁable pathology (termed “normal
skin”), with 1–3 measurements sampled and then averaged at each
location. Measurements were performed at three time points dur-
ing the treatment protocol: (1) prior to administration of ALA, (2)
following 1-h. incubation with ALA and before light illumination,
and (3) immediately following administration of the therapeutic
 70). Marks above bars denote patients on which data only available on AK.
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aig. 2. (a) Shows PpIX yield is higher in AK than non-AK sites, and (b) shows PpIX
orso).
ight dose. All measurements were recorded with the probe tip in
entle contact with the surface of the skin. Recorded white light
pectra were used to estimate a factor that corrected sampled ﬂuo-
escence remission for the inﬂuence of background absorption and
cattering properties.
Fluorescence spectra were ﬁt using a linear combination of basis
pectra from autoﬂuorescence, PpIX, and photoproducts [20]. Fit-
ed PpIX estimates were converted into concentration estimates
sing a linear standard curve generated in an optical phantom. PpIX
oncentration measured on AK lesions was compared with pain
eported during treatment for 70 patients and with PpIX measured
n non-pathologic locations within the treated ﬁeld for 63 patients.
pIX concentrations in AK lesions located on the face (n = 50) were
ompared with measurements from AK lesions located on the body,
hich included arms, leg, and trunk (n = 20). For patients enrolled
n a follow-up survey, PpIX concentrations measured in treated
K lesions were compared with pain and self-reported erythema
xperienced over the 48–72 h following treatment (n = 13).
Measured PpIX concentrations were not normally distributed,
s conﬁrmed by the Kolmogorov–Smirnov test. PpIX concentra-
ion was compared between groups of patients reporting low
ain (VAS < 5) and high pain (VAS ≥5), as well as between mea-
urement locations. These comparisons were performed using the
on-parametric Kruskal–Wallis one-way analysis of variance. Cor-
elations between (i) PpIX concentration measured on AK with
on-pathological locations, (ii) PpIX concentration measured on
K locations with pain reported on the day of treatment, and (iii)
pIX concentration measured on AK locations with pain and ery-
hema reported on follow-up, were calculated using the Pearson
roduct-moment correlation coefﬁcient, with the interpretation
f correlations given as weak (r < 0.33), moderate (0.33 ≤ r < 0.66),
nd strong (r ≥ 0.66). Statistical signiﬁcance for all tests was deter-
ined by p < 0.05. All statistics were performed using the MATLAB
R2015a (The Mathworks Inc., Natick, MA)  Statistics toolbox.
. Results
Fig. 1 shows PpIX concentration measured on AK lesions for
ll sampled patients (n = 70). The data show high inter-patient
ariability in PpIX concentration, with a standard deviation that
xceeds the mean [0.35 ± 0.40] M.  Many patients presented very
ow PpIX accumulation in sampled AK lesions, a factor that is high-
ighted by 45% of lesions falling in the bottom 5% of the sampled
pIX range [0–1.51] M.  Comparison of PpIX concentration sam-
led on AK lesions with normal locations on a per-patient basis
eveals a few interesting aspects. First, AK lesions showed signiﬁ-
antly elevated PpIX concentration compared with measurements
n non-AK locations (p < 0.001) as shown in Fig. 2(a), with an
verage of a 5-fold increase on a per-patient basis. While not allFig. 3. Shows the change PpIX concentration during therapeutic light dose vs. the
PpIX  concentration measured prior to light dose. A linear ﬁt to the data yields a slope
equivalent to the average photobleaching percentage of 72 %.
patients exhibited such an increase, the aggregate data suggest
that selectivity is achieved within this patient population. Sec-
ond, PpIX concentration measured in lesions and normal locations
showed a signiﬁcant moderate correlation (r = 0.55, p < 0.001), sug-
gesting that PpIX production rates are patient-speciﬁc. Fig. 2(b)
shows that the location of the AK lesion inﬂuenced PpIX produc-
tion, with measurements on the face yielding signiﬁcantly higher
PpIX concentration than on other areas on the body (p < 0.001).
Optical measurements were used to estimate both the total
amount of PpIX generated prior to treatment and the differ-
ence in PpIX concentration measured before and after therapeutic
light dose, with the differential calculation representing the total
amount of photosensitizer consumed during the photochemical
reaction during therapy. Interestingly, PpIX concentration prior to
treatment was  highly correlated (r = 0.89, p < 0.001) with the abso-
lute decrease in PpIX experienced during treatment. Fig. 3 shows
paired estimates of the change in PpIX concentration during treat-
ment vs. the PpIX concentration prior to light dose for each patient,
with the average patient experiencing a reduction in PpIX concen-
tration of 72 ± 25% during treatment. These observations suggest
that PpIX yield prior to treatment was  representative of the total
dose, and suggests that these treatments were not limited by vari-
ations in therapeutic light dose.
Fig. 4(a) shows PpIX concentration vs. pain reported on the day
of treatment. The aggregate data show a trend that PpIX concentra-
tion was  higher for patients reporting higher amounts of pain; these
data showed a weak but signiﬁcant positive correlation (r = 0.33,
p < 0.006). Fig. 4(b) shows that PpIX accumulation was  signiﬁcantly
higher in patients reporting high (VAS ≥ 5) vs. low (VAS < 5) pain
(p < 0.022). Inspection of the data in Fig. 4(b) show that patients
with high PpIX concentration overwhelmingly reported high pain,
with 91% of patients above the mean PpIX concentration reporting
564 S. Kanick et al. / Photodiagnosis and Photodynamic Therapy 12 (2015) 561–566
Fig. 4. (a) Shows PpIX yield vs. pain reported on the day of treatment for all patients, and (b) shows that PpIX is higher for patients reporting high amounts of pain (i.e.
VAS  ≥ 5).
Table 1
Details of patients completed follow-up survey. Patient response data include pain reported on the day of treatment, pain and erythema reported for the 2–3 days following
treatment.








PpIX [M] before Tx
51 Forehead 9 9.5 2 0.44
54  Cheek 0 1.5 1 0.12
55  Chest 4 5 2 0.12
56  Cheek 6 5.5 2 1.01
57  Forehead 6 0 1 0.13
58  Forehead 3 4.5 1 0.07
64  Lip/Chin 3 8 2 0.29
65  Forehead 5 5 2 0.12
66  Hand 4 3 1 0.03
































t68  Forehead 8 
69  Hand 8 
70  Arm 3 
igh pain. Conversely, low PpIX concentration was not an exclusive
ndicator of low pain, with 55% of patients presenting PpIX concen-
rations in the bottom 5% of the sampled range reporting high pain.
hese data indicate that while high PpIX concentration is predictive
f high pain, low PpIX concentration was not an indicator of low
ain. The latter results are likely explained by patient-speciﬁc vari-
tion in pain tolerance and points to the clear limitations of pain as
n indicator of therapeutic response.
A follow-up phone survey was administered to a subset of
atients (n = 13) to examine potential correlations between PpIX
oncentration and longer-term pain and redness effects. Table 1
resents data on patient-reported pain and erythema experienced
ver the 48–72 h following treatment. Interestingly, PpIX concen-
ration measured in this subset of patients showed no correlation
ith pain reported on the day of treatment (r = 0.17, p < 0.57), but
 signiﬁcant moderate correlation with pain reported on follow
p was obtained (r = 0.55, p < 0.050). Moreover, PpIX concentration
as moderately correlated with the degree of erythema reported
n follow up (r = 0.58, p < 0.039), while pain reported on the day
f treatment showed no predictive value for erythema (r = 0.02,
 < 0.939). Comparison of optical data with results from the follow
p showed a signiﬁcantly higher PpIX yield in patients report-
ng high levels of pain on follow up (p < 0.046) and higher PpIX
n patients reporting mild (1) vs. severe (2) erythema (p < 0.045).
hese data suggest that for patients with low PpIX concentration,
ain reported on the day of treatment was not a quality indica-
or of response in the days following treatment. Conversely, PpIX
oncentration measured on the day of treatment was  a strong pre-





Optical quantiﬁcation of PpIX generation provides important
insights into short contact ALA-PpIX PDT treatments for AK.
We observed substantial variability in PpIX accumulation among
patients, with the majority of lesions presenting low amounts of
PpIX. These data suggest that many patients may be receiving low
therapeutic doses, with treatments potentially limited by inade-
quate supply of photosensitizer. These observations are consistent
with previous ALA-PpIX studies reporting substantial variation
in time-dependent PpIX generation [21–23], and total PpIX yield
[19,20]. Differences in PpIX concentration were dependent on the
location of the lesion, with increased levels observed in lesions
located on the face as compared with lesions elsewhere on the body.
There are multiple reasons for this observation. First, the stratum
corneum may  be thinner on the face than elsewhere (i.e. hands,
arms, legs, chest) [24] and may  represent a reduced barrier to ALA
distribution, and in turn increased PpIX production in the face. Sec-
ond, skin temperature may  be lower on extremities than on the face,
resulting in lower PpIX generation on the arms and legs [25]. The
observed differences in PpIX generation also appear to be patient-
speciﬁc, with a correlation observed between PpIX concentration
in AK lesions and normal locations on a per-patient basis. Such
differences may  be attributable to molecular aspects of the heme-
synthesis cycle that may  make some lesions or tumors more likely
to produce higher amounts of PpIX than others [26]. Our data show
that dosimetric evaluation of PpIX can identify patients presenting
low PpIX yields at the time of treatment administration. Identiﬁca-
tion of potential non-responding patients at the time of treatment





































































[S. Kanick et al. / Photodiagnosis and P
uction, possibly through increased contact time, re-application of
LA after lesion debridement, temperature modulation [27,28], or
hrough administration of a penetration enhancing [29] or differ-
ntiating agents [30–33]. This approach to optical dosimetry during
LA-PpIX PDT for AK may  be an important piece to an approach to
tandardize the therapeutic dose on a patient-speciﬁc basis.
The current study identiﬁes a correlation between the amount
f PpIX yield generated during the drug light interval and the
esponse noted by the patient, as measured by pain and ery-
hema. Previous studies have utilized PpIX ﬂuorescence intensity
s a biomarker for delivered dose, with some studies considering
he percentage of ﬂuorescence bleached during treatment [34,35],
hile others considering the absolute amount of PpIX ﬂuorescence
enerated and/or bleached [19,20]. Our data show that the quanti-
ative assessment of PpIX concentration prior to therapeutic light
ose was highly correlated with the total PpIX change between
efore and after light dose. These observations suggest that even a
ingle measurement of PpIX assessed prior to therapeutic illumi-
ation may  be sufﬁcient to identify non-responding patients.
The hypothesis underlying this study is that quantitative assess-
ent of amount of PpIX generated prior to treatment is an
mportant biomarker for the delivered PDT dose. Previous stud-
es have shown a correlation between PpIX accumulation and pain
36] and erythema [37] and others have noted that PpIX accumu-
ation above a ‘threshold’ was correlated with complete treatment
esponse [19]. Our data show that patients presenting above aver-
ge PpIX concentration overwhelmingly reported high levels of
ain on the day of treatment. While low PpIX yields were not
n indicator of low pain on the day of treatment, the subset of
ata from follow-up survey suggests that PpIX measurements are
ell-correlated with pain and erythema experienced in the days
fter treatment. Previously, erythema was considered as part of a
echanistic investigation of PDT response [38,39], and therefore
ay  represent a meaningful surrogate metric of delivered photo-
ynamic dose.
Interpretation of the potential clinical impact of the results pre-
ented in this study requires consideration of the patient sample
ize included in the follow-up group (n = 13). The follow-up data
how clear and signiﬁcant differences in the PpIX concentration
easured in patients reporting no redness and those reporting
evere erythema 48–72 h following treatment. It is important to
ote that erythema was not well-correlated with pain reported on
he day of treatment, suggesting that optical measurements of PpIX
ay  be a more reliable indicator of response. While these data sup-
ort the claim that optical measurements of PpIX may  differentiate
etween patients expected to have no response compared with
 severe response, the small patient total in the follow-up group
imits conclusions about a more granular prediction of response
long a continuum of severity (e.g. mild, moderate, severe, etc.), as
uch conclusions would require follow-up data from an expanded
atient population.
The current study utilizes pain and erythema as metrics of treat-
ent response, which the authors recognize are subjective and
ay  be limited by patient-speciﬁc variation in pain sensitivity
40,41]. While follow-up appointments are the most reasonable
pproach to evaluate therapeutic outcome, they require a substan-
ial resource commitment both from the clinic and the patient.
oreover, assessment of AK clearance after treatment can be com-
licated, especially over a time frame of multiple months, as it
an be difﬁcult to differentiate incomplete responding lesions from
he formation of new lesions [42]. It should also be noted that
valuation of lesion clearance is not a direct indicator of develop-
ent of squamous cell carcinoma (SCC), the most immediate health
isk posed by prolonged AK [1]; such an evaluation would require
 long-term study with intensive follow up. The data presented
ithin the current study motivate the incorporation of quantitative
[
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measurements into a long-term evaluation of ALA-PpIX PDT treat-
ments for AK, as the optical measurements would provide insight
into incomplete responses and also provide a method to potentially
intervene with patients presenting low PpIX without the need to
wait for follow-up.
5. Conclusions
Optical measurements of PpIX concentration showed high inter-
patient variability with a substantial sub-population of patients
presenting very low levels of PpIX accumulation prior to PDT. The
presented data suggest that measurement of PpIX concentration
may  be a more reliable and objective biomarker of delivered PDT
dose than patient reported pain during treatment, and may  be
more cost-effective than follow up appointments. Moreover, the
data suggest that measuring PpIX concentration prior to therapeu-
tic illumination may  identify non-responding patients, potentially
facilitating the use of additional interventions to improve out-
comes.
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